FindTrial
Sign In

ProFaMa neoadjuvant: Diagnostic value of tumourmarkers measured in activated macrophages during neoadjuvant treatment of breast cancer.

ProFaMa neoadjuvant: Diagnostic value of tumourmarkers measured in activated macrophages during neoadjuvant treatment of breast cancer. - ProFaMa neoadjuvant

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32754
Enrollment
40
Registered
2009-12-31
Start date
2010-01-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Sponsors

Heelkunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Men and women diagnosed with primary or recurring breast cancer who will receive neoadjuvant systemic therapy.

Exclusion criteria

Exclusion criteria: Not being able to agree with the informed consent procedure.

Design outcomes

Primary

MeasureTime frame
This research will focus on women with a locally or advanced carcinoma of the breast and who will receive neoadjuvant treatment in the Atrium Medisch Centrum in Heerlen. The primary outcome will be the changes in concentration of tumourmarker containing macrophages in relation to changes in tumour size as measured by MRI and pathologic respons.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)